Guard Therapeutics International (OM:GUARD) - Cotización, noticias y análisis

Resumen de acción GUARD

Guard Therapeutics International AB (publ), empresa farmacéutica, identifica, desarrolla y comercializa en Suecia terapias para el diagnóstico y tratamiento de lesiones renales agudas.

Acerca de la empresa

GUARD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares (SEK0)

Tiene menos de 1 año de cash runway

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

No tiene una capitalización de mercado significativa (SEK308M)

+ 1 riesgos adicionales

Competidores de Guard Therapeutics International AB (publ)

Oncopeptides

OM:ONCO

kr287.9m

Intervacc

OM:IVACC

kr331.3m

Curasight

NGM:CURAS

kr.197.7m

Xbrane Biopharma

OM:XBRANE

kr314.3m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Guard Therapeutics International
Historical stock prices
Current Share Price	kr30.00
52 Week High	kr49.80
52 Week Low	kr5.10
Beta	-0.020
1 Month Change	71.43%
3 Month Change	32.74%
1 Year Change	408.47%
3 Year Change	-60.53%
5 Year Change	-39.15%
Change since IPO	-99.67%

Noticias y actualizaciones recientes

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

Apr 18

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

Jan 04

Recent updates

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

Apr 18

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

Jan 04

Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

Sep 20

Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans

Apr 06

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Sep 09

Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Feb 19

We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Aug 17

Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth

Apr 19

Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Jan 04

Rentabilidad de los accionistas

	GUARD	SE Biotechs	Mercado SE
7D	0.7%	0.5%	1.1%
1Y	408.5%	-3.8%	10.2%

Rentabilidad vs. Industria: GUARD superó al sector Swedish Biotechs , que obtuvo un rendimiento del -3.2% el año pasado.

Rentabilidad vs. Mercado: GUARD superó al mercado Swedish, que obtuvo un rendimiento del 10.3% el año pasado.

Volatilidad de los precios

Is GUARD's price volatile compared to industry and market?
GUARD volatility
GUARD Average Weekly Movement	12.4%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in SE Market	13.3%
10% least volatile stocks in SE Market	3.6%

Precio estable de las acciones: El precio de las acciones de GUARD ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de GUARD ha disminuido de 35% a 12% en el último año, pero sigue siendo superior al 75% de los valores de Swedish.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2008	11	Tobias Agervald	guardtherapeutics.com

Guard Therapeutics International AB (publ), empresa farmacéutica, identifica, desarrolla y comercializa en Suecia terapias para el diagnóstico y tratamiento de lesiones renales agudas. Ofrece ROSGard, un fármaco biológico candidato que previene las lesiones renales protegiendo, limpiando y reparando las células y tejidos expuestos. La compañía era conocida anteriormente como A1M Pharma AB (publ) y cambió su nombre a Guard Therapeutics International AB (publ) en octubre de 2019.

Resumen de fundamentos de Guard Therapeutics International AB (publ)

¿Cómo se comparan los beneficios e ingresos de Guard Therapeutics International con su capitalización de mercado?
Estadísticas fundamentales de GUARD
Capitalización bursátil	kr301.85m
Beneficios(TTM)	-kr113.32m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-2.7x

Ratio precio-beneficio (PE)

¿Está GUARD sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de GUARD
Ingresos	kr0
Coste de los ingresos	kr0
Beneficio bruto	kr0
Otros gastos	kr113.32m
Beneficios	-kr113.32m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-11.26
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado GUARD a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción GUARD

Recompensas

Análisis de riesgos

Competidores de Guard Therapeutics International AB (publ)

OM:ONCO

kr287.9m

OM:IVACC

kr331.3m

NGM:CURAS

kr.197.7m

OM:XBRANE

kr314.3m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

No longer forecast to breakeven

New major risk - Share price stability

New major risk - Financial position

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

New major risk - Revenue and earnings growth

Recent updates

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

No longer forecast to breakeven

New major risk - Share price stability

New major risk - Financial position

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

New major risk - Revenue and earnings growth

Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 (Akita) and Advances Clinical Development Program

Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

New minor risk - Financial position

New major risk - Revenue and earnings growth

Guard Therapeutics International AB Announces Completion of Clinical Phase 2 Study AKITA

Guard Therapeutics Announces the Full Results from the Phase 1B Clinical Study of the Investigational Drug RMC-035 in Patients Undergoing Kidney Transplantation

Price target decreased by 36% to kr1.61

No longer forecast to breakeven

Price target decreased by 36% to kr1.61

Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans

No longer forecast to breakeven

Guard Therapeutics Announces First Patient in US Dosed with Study Drug in the Ongoing Global Phase 2 Clinical Trial AKITA

Guard Therapeutics International AB (Publ) Announces 134 of the Planned 268 Patients Have Been Dosed in the Global Randomized, Double-Blinded and Placebo-Controlled Phase 2 Clinical Trial

No longer forecast to breakeven

Guard Therapeutics International AB (publ) Receives FDA Fast Track Designation for RMC-035

Guard Therapeutics International AB (publ) Receives IND Approval from the FDA for RMC-035

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Guard Therapeutics Announces That the First Patient Has Been Dosed in A Phase 1b Clinical Trial of the Investigational Drug RMC-035 (ROSgard) in Kidney Transplantation

Guard Therapeutics Announces That the First Patient Has Been Dosed in A Phase 1b Clinical Trial of the Investigational Drug RMC-035 (ROSgard) in Kidney Transplantation

Guard Therapeutics Receives Approval from the Swedish Medical Products Agency to Conduct A Clinical Study of RMC-035 in Kidney Transplantation

Price target decreased to kr2.15

High number of new and inexperienced directors

Guard Therapeutics International AB (publ) Appoints Torbjörn Larsson as Head of CMC (Chemistry, Manufacturing and Controls), Effective 1 May 2022

Guard Therapeutics International AB (publ) Provides In-Depth Information on Phase 2 Clinical Trial

Guard Therapeutics Announces First Patient Has Been Dosed in Guard Therapeutics' Phase 2 Clinical Trial of ROSgard

Forecast to breakeven in 2024

Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Chief Executive Officer recently bought kr1.6m worth of stock

Guard Therapeutics Receives Approval to Expand the Global Phase 2 Study of Rosgard to Canada

Guard Therapeutics’ Application to Conduct a Phase 2 Clinical Trial of ROSgard is Approved by the German Medicines Regulator

Chief Executive Officer recently bought kr300k worth of stock

Guard Therapeutics International AB (Publ) Reports Positive Results from Preclinical Studies

We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth

Guard Therapeutics appoints Sara Thuresson as Head of Clinical Operations

New 90-day high: kr1.50

Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Guard Therapeutics International AB (Publ) Completes Pre-IND meeting with FDA

Guard Therapeutics Appoints Ann-Kristin Myde as Head of Global Project Management, Effective 1 April 2021

New 90-day low: kr1.22

New 90-day low: kr1.23

Guard Therapeutics Reports Positive Top-Line Results from Phase 1 Study of Rosgard in Individuals with Renal Impairment

New 90-day high - kr1.60

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Guard Therapeutics International AB (publ)

0.0x

-2.7x

Beneficios e Ingresos